Bimagrumab + semaglutide — myostatin inhibitor combo for body recomp

roxy_nash said:

The mechanism that matters here is not stomach emptying, it is central.

Bookmarking. The distinction being drawn above is the one nobody else makes. I will report back once I have actually tried it.

Adding the clinical framing, because it changes how the question reads.

MikeFit_NJ said:

...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.

Dr.SleepRoch said:

Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Adding the numbers, since they settle part of this. One habit that pays for itself: post the method alongside the number. A figure without its method cannot be checked, and an unchecked figure is how this community accumulates folklore.

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Carry on.